1. WHO Expert Committee on Biological Standardization.2013. Annex 2. Guidelines on evaluation of similar biotherapeutic products (SBPs). WHO Technical Report Series no. 977. http://who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf Accessed 12 Nov 2021.
2. Kang HN, Thorpe R, Knezevic I, Survey participants from 19 countries. The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019. Biologicals. 2020;65:1–9. https://doi.org/10.1016/j.biologicals.2020.02.005.
3. World Health Organization Expert Committee on Biological Standardization. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs). In: sixty-seventh report, WHO technical report series 1004, 93–127. http://apps.who.int/iris/bitstream/10665/255657/1/9789241210133-eng.pdf. Accessed 12 Nov 2021.
4. World Health Organization. Questions and Answers: similar biotherapeutic products. 2018. https://www.who.int/biologicals/expert_committee/QA_for_SBPs_ECBS_2018.pdf?ua=. Accessed 12 Nov 2021.
5. WHO Expert Committee on Biological Standardization: Report of the seventy-second and seventy-third meetings. Geneva: World Health Organization; 2021 (WHO Technical Report Series, No. 1030; https://www.who.int/publications/i/item/9789240024373) Accessed 13 May 2022.